Kamal Kishor¹, Dr Syamantak Mani Tripathi¹*, Apoorva Mishra², Randhir Singh², Vandana Gupta³, Pramod Sharma⁴, Amit Singh Vishen⁵, Neha Shukla⁶, Mayank Soni², Aditya Mishra⁷ and Rajesh Kumar Sharma¹

¹Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science and A.H., Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, Bharat
²Department of Veterinary Surgery and Radiology, College of Veterinary Science and A.H., Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, Bharat
³Department of Veterinary Microbiology, College of Veterinary Science and A.H., Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, Bharat
⁴Department of Animal Nutrition, College of Veterinary Science and A.H., Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, Bharat
⁵Department of Veterinary Anatomy, CoVAS, Rani Lakshmi Bai Central Agricultural University (RLBCAU), Jhansi, Uttar Pradesh, Bharat
⁶Department of Veterinary Pathology, College of Veterinary Science and A.H., Durg, Dau Shri Vasudev Chnadrakar Kamdhenu Vishwavidyalaya, Durg, Chhattisgarh, Bharat
⁷Department of Veterinay Physiology and Biochemistry in lieu of Veterinary and Biochemistry, College of Veterinary Science and A.H., Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, Bharat, E-mail : dr.adityamishra@gmail.com

*Corresponding Author: Dr. Syamantak Mani Tripathi, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science and A.H., Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, Bharat.

Received: June 13, 2024; Published: July 15, 2024

Abstract

Cytokines, intricate signaling molecules crucial for immune regulation, hold immense therapeutic promise for immune-related disorders. Despite their multifaceted roles spanning inflammation, immune cell differentiation, and tumorigenesis, clinical translation of cytokine-based therapies faces significant hurdles, including short half-lives and systemic side effects. Pleiotropism, intrinsic to cytokines, underscores both their therapeutic potential and the complexities in their clinical application. Cutting-edge cytokine engineering technologies have emerged, offering novel avenues for immunotherapeutics, particularly in advanced cancer treatment. However, challenges persist, prompting the development of tailored therapeutic strategies. Noteworthy advancements include recombinant IL-1 receptor antagonist Anakinra and engineered cytokine antagonists, addressing specificity and efficacy concerns. Precision medicine approaches herald a paradigm shift in cytokine-based therapy, facilitating targeted interventions tailored to individual patient profiles. This comprehensive review delineates existing challenges in cytokine-based therapies while elucidating innovative strategies poised to unlock their full clinical potential. By addressing limitations and leveraging the transformative power of cytokines, this review signals a new era of precision immunotherapy with profound implications for patient care and therapeutic efficacy.

Keywords: Adipokines; Chemokines; Cytokine Engineering; Cytokines; Cytokine Immunotherapy; Immuno Cytokines; Leptin; Modulation Strategies; Muteins; Neokines; Prodrug; Resistin

References

1. Deckers Jeroen., et al. "Author Correction: Engineering cytokine therapeutics”. Nature Reviews Bioengineering4 (2023): 304-304.
2. Yue Tong., et al. "The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications”. Frontiers in Immunology13 (2022): 1055087.
3. Arango Duque Guillermo and Albert Descoteaux. "Macrophage cytokines: involvement in immunity and infectious diseases”. Frontiers in Immunology5 (2014): 117833.
4. Hughes Catherine E and Robert JB Nibbs. "A guide to chemokines and their receptors”. The FEBS Journal16 (2018): 2944-2971.
5. Roan Florence., et al. "Epithelial cell–derived cytokines: more than just signaling the alarm”. The Journal of Clinical Investigation4 (2019): 1441-1451.
6. Scheller Jürgen., et al. "The pro-and anti-inflammatory properties of the cytokine interleukin-6”. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research5 (2011): 878-888.
7. Hernandez Rosmely., et al. "Engineering IL-2 for immunotherapy of autoimmunity and cancer”. Nature Reviews Immunology10 (2022): 614-628.
8. Kozlowski Steven Barry Cherney and Raymond P Donnelly. "Hurdles and leaps for protein therapeutics: cytokines and inflammation”. Annals of the New York Academy of Sciences1 (2009): 146-160.
9. Leonard Warren J and Jian-Xin Lin. "Strategies to therapeutically modulate cytokine action”. Nature Reviews Drug Discovery10 (2023): 827-854.
10. Campuzano Susana Paloma Yáñez-Sedeño and José Manuel Pingarrón. "Revisiting electrochemical biosensing in the 21st century society for inflammatory cytokines involved in autoimmune, neurodegenerative, cardiac, viral and cancer diseases”. Sensors1 (2020): 189.
11. Donnelly Raymond P., et al. "An overview of cytokines and cytokine antagonists as therapeutic agents”. Annals of the New York Academy of Sciences1 (2009): 1-13.
12. Kawamura Masaru., et al. "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes”. Proceedings of the National Academy of Sciences14 (1994): 6374-6378.
13. Feng Jian., et al. "Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop”. Molecular and cellular biology (1997).
14. Schindler C and J E Darnell Jr. "Transcriptional responses to polypeptide ligands: the JAK-STAT pathway”. Annual Review of Biochemistry1 (1995): 621-652.
15. Morris Rhiannon., et al. "The molecular details of cytokine signaling via the JAK/STAT pathway”. Protein Science12 (2018): 1984-2009.
16. Gadina Massimo., et al. "Signaling by type I and II cytokine receptors: ten years after”. Current Opinion in Immunology3 (2001): 363-373.
17. Shuai Ke and Bin Liu. "Regulation of gene-activation pathways by PIAS proteins in the immune system”. Nature Reviews Immunology8 (2005): 593-605.
18. Nekoui Alireza and Gilbert Blaise. "Erythropoietin and nonhematopoietic effects”. The American Journal of the Medical Sciences1 (2017): 76-81.
19. Waldmann Thomas A. "The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy”. Cancer Immunology Research3 (2015): 219-227.
20. Harris J Milton and Robert B Chess. "Effect of pegylation on pharmaceuticals”. Nature Reviews Drug Discovery3 (2003): 214-221.
21. Miyazaki Takahiro., et al. "NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy”. Journal for ImmunoTherapy of Cancer5 (2021).
22. Sellaturay Priya., et al. "Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine”. Clinical and Experimental Allergy6 (2021): 861.
23. Pasche Boris. "Role of transforming growth factor beta in cancer”. Journal of Cellular Physiology2 (2001): 153-168.
24. Pastan Ira., et al. "Immunotoxin therapy of cancer”. Nature Reviews Cancer7 (2006): 559-565.
25. Presta Marco., et al. "Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach”. Pharmacology and Therapeutics179 (2017): 171-187.
26. Charych Deborah H., et al. "NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models”. Clinical Cancer Research3 (2016): 680-690.
27. Momin Noor., et al. "Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy”. Science Translational Medicine498 (2019): eaaw2614.
28. Agarwal Yash., et al. "Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity”. Nature Biomedical Engineering2 (2022): 129-143.
29. Ishihara Jun., et al. "Targeted antibody and cytokine cancer immunotherapies through collagen affinity”. Science Translational Medicine487 (2019): eaau3259.
30. Hsu Eric J., et al. "A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy”. Nature Communications1 (2021): 2768.
31. Rosen David Brian., et al. "TransConTM IL-2 β/γ: a novel long-acting prodrug of receptor-biased IL-2 designed for improved pharmocokinetics and optimal activation of T cells for the treatment of cancer”. Cancer Research16 (2020): 4507-4507.
32. Jones CDea., et al. "The HadGEM2-ES implementation of CMIP5 centennial simulations”. Geoscientific Model Development3 (2011): 543-570.
33. Smith RA., et al. “Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening”. CA: A Cancer Journal for Clinicians 68.4 (2018): 297-316.
34. Brown J William L., et al. "Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis”. Jama2 (2019): 175-187.
35. Wang Dawei., et al. "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China”. jama11 (2020): 1061-1069.
36. Jones Veena G., et al. "COVID-19 and Kawasaki disease: novel virus and novel case”. Hospital pediatrics6 (2020): 537-540.
37. Lansigan Frederick., et al. "Phase I/II study of an anti-CD20-interleukin-2 immunocytokine DI-Leu16-IL2 in patients with relapsed b-cell lymphoma (NHL)”. (2016).
38. Gardner Wilford D., et al. "Global comparison of benthic nepheloid layers based on 52 years of nephelometer and transmissometer measurements”. Progress in Oceanography168 (2018): 100-111.
39. Smith Robert A., et al. "Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening”. CA: A Cancer Journal for Clinicians3 (2019): 184-210.
40. Harrison C M., et al. "The KMOS AGN Survey at High redshift (KASH z): the prevalence and drivers of ionized outflows in the host galaxies of X-ray AGN”. Monthly Notices of the Royal Astronomical Society2 (2016): 1195-1220.
41. Chen Peter., et al. "SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19”. New England Journal of Medicine3 (2021): 229-237.
42. Tan, Bee Ling., et al. "Antioxidant and oxidative stress: a mutual interplay in age-related diseases”. Frontiers in Pharmacology9 (2018): 402374.
43. Parker Michael J., et al. "Ethics of instantaneous contact tracing using mobile phone apps in the control of the COVID-19 pandemic”. Journal of Medical Ethics7 (2020): 427-431.
44. Peterson LB., et al. “A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease”. Journal of Autoimmunity95 (2018): 1-14.
45. Silva Daniel-Adriano., et al. "De novo design of potent and selective mimics of IL-2 and IL-15”. Nature7738 (2019): 186-191.
46. Harris Katherine E., et al. "A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells”. Scientific Reports1 (2021): 10592.
47. Yen Michelle., et al. "Facile discovery of surrogate cytokine agonists”. Cell8 (2022): 1414-1430.
48. Saxton Robert A., et al. "Emerging principles of cytokine pharmacology and therapeutics”. Nature Reviews Drug Discovery1 (2023): 21-37.
49. Stephan Blossom CM., et al. "Dementia risk prediction in the population: are screening models accurate?”. Nature Reviews Neurology6 (2010): 318.
50. Zhang Yuan., et al. "Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity”. Nature Communications1 (2018): 6.
51. Ciliberto G. “Cytokine inhibitors”. CRC Press (2000).
52. Schade Rüdiger., et al. "Chicken egg yolk antibodies (IgY-technology): a review of progress in production and use in research and human and veterinary medicine”. Alternatives to Laboratory Animals2 (2005): 129-154.
53. Philips Rachael L., et al. "The JAK-STAT pathway at 30: Much learned, much more to do”. Cell21 (2022): 3857-3876.
54. Hu Xiaoyi., et al. "The JAK/STAT signaling pathway: from bench to clinic”. Signal transduction and targeted therapy1 (2021): 402.
55. Monaghan Kelly Lynn., et al. "Tetramerization of STAT5 promotes autoimmune-mediated neuroinflammation”. The Journal of Immunology1 (2022): 44-05.
56. Smith Lee., et al. "Correlates of symptoms of anxiety and depression and mental wellbeing associated with COVID-19: a cross-sectional study of UK-based respondents”. Psychiatry Research291 (2020): 113138.
57. Harmon-Jones, Eddie Ed. Cognitive dissonance: Reexamining a pivotal theory in psychology. American Psychological Association, (2019).
58. Brown Catherine M. "Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings—Barnstable County, Massachusetts, July 2021”.  Morbidity and Mortality Weekly Report70 (2021).
59. Nalawansha Dhanusha A., et al. "Targeted protein internalization and degradation by ENDosome TArgeting Chimeras (ENDTACs)”. ACS Central Science6 (2019): 1079-1084.

Citation

Citation: Dr. Syamantak Mani Tripathi., et al. “Cytokine Engineering: Revolutionizing Therapeutics and Immune Modulation”.Acta Scientific Medical Sciences 8.8 (2024): 95-107.

Copyright

Copyright: © 2024 Dr. Syamantak Mani Tripathi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.